{"id":10203,"date":"2026-07-07T08:37:54","date_gmt":"2026-07-07T13:37:54","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10203"},"modified":"2026-07-07T10:59:27","modified_gmt":"2026-07-07T15:59:27","slug":"catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","title":{"rendered":"Catalent\u793e\u3068Nanoscope Therapeutics\u793e\u304c\u63d0\u643a\u95a2\u4fc2\u3092\u62e1\u5927\u3057\u3001\u4e3b\u8981\u306a\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u85acMCO-010\u306e\u5f8c\u671f\u958b\u767a\u304a\u3088\u3073\u5546\u696d\u4f9b\u7d66\u3092\u652f\u63f4\u3059\u308b\u3002"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u30c0\u30e9\u30b9<\/span>,\u00a02026\u5e747\u67087\u65e5<\/span><\/strong>\u00a0\u2014\u00a0\u30ab\u30bf\u30ec\u30f3\u30c8<\/a>, \u4e16\u754c\u4e2d\u306e\u60a3\u8005\u306b\u3088\u308a\u826f\u3044\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u30fb\u63d0\u4f9b\u3059\u308b\u3053\u3068\u3092\u53ef\u80fd\u306b\u3059\u308b\u30ea\u30fc\u30c0\u30fc\u3067\u3042\u308a\u3001\u00a0\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/a>, \u7db2\u819c\u5909\u6027\u306b\u3088\u308b\u5149\u53d7\u5bb9\u4f53\u55aa\u5931\u60a3\u8005\u5411\u3051\u306b\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u65b0\u898f\u306e\u8996\u529b\u56de\u5fa9\u7642\u6cd5\u3092\u5546\u696d\u5316\u3059\u308b\u3053\u3068\u306b\u5c3d\u529b\u3057\u3066\u3044\u308b\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bNanoscope\u306f\u672c\u65e5\u3001\u540c\u793e\u306e\u4e3b\u8981\u306a\u5149\u907a\u4f1d\u5b66\u7684\u907a\u4f1d\u5b50\u6cbb\u7642\u85ac\u3067\u3042\u308bMCO-010\u306e\u5f8c\u671f\u81e8\u5e8a\u8a66\u9a13\u304a\u3088\u3073\u5546\u696d\u4f9b\u7d66\u3092\u652f\u63f4\u3059\u308b\u305f\u3081\u306e\u63d0\u643a\u95a2\u4fc2\u306e\u62e1\u5927\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002.<\/p>

\u4eca\u56de\u306e\u63d0\u643a\u62e1\u5927\u306b\u4f34\u3044\u3001Catalent\u793e\u306fMCO-010\u306e\u5546\u696d\u57fa\u6e96\u306b\u6e96\u62e0\u3057\u305f\u5305\u88c5\u304a\u3088\u3073\u6d41\u901a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3001Nanoscope\u793e\u306e\u751f\u7269\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u3092\u652f\u63f4\u3059\u308b\u305f\u3081\u306e\u5546\u696d\u5305\u88c5\u691c\u8a3c\u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u78ba\u4fdd\u3057\u307e\u3057\u305f\u3002\u73fe\u5728\u3001\u7c73\u56fd\u98df\u54c1\u533b\u85ac\u54c1\u5c40\uff08FDA\uff09\u3078\u306e\u6bb5\u968e\u7684\u306a\u7533\u8acb\u624b\u7d9a\u304d\u304c\u9032\u3081\u3089\u308c\u3066\u3044\u307e\u3059\u3002.<\/p>

\u201c\u300cMCO-010\u306e\u5546\u696d\u5316\u306b\u5411\u3051\u305f\u9032\u5c55\u306b\u4f34\u3044\u3001Catalent\u306fNanoscope\u3068\u306e\u5354\u696d\u3092\u62e1\u5927\u3067\u304d\u308b\u3053\u3068\u3092\u5b09\u3057\u304f\u601d\u3044\u307e\u3059\u300d\u3068\u3001\u81e8\u5e8a\u30fb\u5c02\u9580\u30b5\u30fc\u30d3\u30b9\u62c5\u5f53\u30b0\u30eb\u30fc\u30d7\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u517c\u30c1\u30fc\u30d5\u30fb\u30aa\u30d6\u30fb\u30b9\u30bf\u30c3\u30d5\u306e\u30ea\u30c3\u30ad\u30fc\u30fb\u30db\u30d7\u30bd\u30f3\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300cCatalent\u306f\u3001\u3053\u306e\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u3092\u5e02\u5834\u306b\u6295\u5165\u3057\u3001\u4e16\u754c\u4e2d\u306e\u60a3\u8005\u3055\u3093\u306e\u8996\u529b\u56de\u5fa9\u3068\u3044\u3046Nanoscope\u306e\u4f7f\u547d\u3092\u5b9f\u73fe\u3067\u304d\u308b\u3088\u3046\u3001\u3042\u3089\u3086\u308b\u6bb5\u968e\u3067Nanoscope\u3092\u652f\u63f4\u3057\u3066\u3044\u304f\u6240\u5b58\u3067\u3059\u3002\u300d\u201d<\/p>

\u201c\u300cMCO-010\u306e\u5546\u696d\u7528\u533b\u85ac\u54c1\u306e\u88fd\u9020\u3092\u7d99\u7d9a\u3057\u3066\u3044\u304f\u4e0a\u3067\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u5546\u696d\u5316\u306e\u30cb\u30fc\u30ba\u3092\u6e80\u305f\u3059\u305f\u3081\u306b\u5171\u306b\u898f\u6a21\u3092\u62e1\u5927\u3067\u304d\u308b\u5305\u88c5\u30d1\u30fc\u30c8\u30ca\u30fc\u3092\u6301\u3064\u3053\u3068\u306f\u4e0d\u53ef\u6b20\u3067\u3059\u300d\u3068\u3001Nanoscope Therapeutics\u306e\u5171\u540c\u5275\u696d\u8005\u517cCEO\u3067\u3042\u308bSulagna Bhattacharya\u6c0f\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300cCatalent\u306e\u5c02\u9580\u77e5\u8b58\u3068\u4fe1\u983c\u6027\u306f\u3001\u3053\u306e\u53d6\u308a\u7d44\u307f\u306e\u6b21\u306e\u6bb5\u968e\u306b\u5411\u3051\u3066\u6e96\u5099\u3092\u9032\u3081\u308b\u79c1\u305f\u3061\u306b\u81ea\u4fe1\u3092\u4e0e\u3048\u3066\u304f\u308c\u307e\u3059\u3002\u7db2\u819c\u5909\u6027\u75be\u60a3\u3092\u62b1\u3048\u308b\u60a3\u8005\u3055\u3093\u306b\u5207\u671b\u3055\u308c\u3066\u3044\u308b\u6cbb\u7642\u9078\u629e\u80a2\u3092\u63d0\u4f9b\u3059\u308b\u305f\u3081\u306b\u3001\u3053\u306e\u30d1\u30fc\u30c8\u30ca\u30fc\u30b7\u30c3\u30d7\u3092\u7d99\u7d9a\u3067\u304d\u308b\u3053\u3068\u3092\u697d\u3057\u307f\u306b\u3057\u3066\u3044\u307e\u3059\u3002\u300d\u201d<\/p>

MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u3084\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306a\u3069\u306e\u9032\u884c\u6027\u7db2\u819c\u5909\u6027\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u305f\u3081\u3001\u7db2\u819c\u7d30\u80de\u3092\u5149\u611f\u53d7\u6027\u306b\u518d\u30d7\u30ed\u30b0\u30e9\u30e0\u5316\u3059\u308b\u3053\u3068\u3067\u958b\u767a\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u3053\u306e\u30a2\u30d7\u30ed\u30fc\u30c1\u306f\u3001\u73fe\u5728\u6cbb\u7642\u9078\u629e\u80a2\u304c\u9650\u3089\u308c\u3066\u3044\u308b\u672b\u671f\u75be\u60a3\u306e\u60a3\u8005\u3092\u6cbb\u7642\u3059\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>

Catalent\u306b\u3064\u3044\u3066<\/b><\/p>

Catalent, Inc.\u306f\u3001\u4eba\u3005\u306e\u3088\u308a\u826f\u3044\u3001\u3088\u308a\u5065\u5eb7\u7684\u306a\u751f\u6d3b\u3092\u652f\u63f4\u3059\u308b\u3068\u3044\u3046\u4f7f\u547d\u3092\u63a8\u9032\u3059\u308b\u3001\u4e16\u754c\u6709\u6570\u306e\u533b\u85ac\u54c1\u53d7\u8a17\u958b\u767a\u88fd\u9020\u6a5f\u95a2\uff08CDMO\uff09\u3067\u3059\u3002Catalent\u304c\u958b\u767a\u3001\u88fd\u9020\u3001\u4e0a\u5e02\u3092\u652f\u63f4\u3059\u308b\u3059\u3079\u3066\u306e\u88fd\u54c1\u306f\u3001\u60a3\u8005\u7b2c\u4e00\u4e3b\u7fa9\u306e\u30a2\u30d7\u30ed\u30fc\u30c1\u3092\u901a\u3058\u3066\u4e16\u754c\u4e2d\u306e\u5065\u5eb7\u72b6\u614b\u306e\u6539\u5584\u306b\u8ca2\u732e\u3059\u308b\u3068\u3044\u3046\u540c\u793e\u306e\u30b3\u30df\u30c3\u30c8\u30e1\u30f3\u30c8\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059\u3002Catalent\u306f\u3001\u88fd\u85ac\u3001\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3001\u30b3\u30f3\u30b7\u30e5\u30fc\u30de\u30fc\u30d8\u30eb\u30b9\u30b1\u30a2\u306e\u304a\u5ba2\u69d8\u306b\u6bd4\u985e\u306e\u306a\u3044\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3001\u4eba\u3005\u306e\u751f\u6d3b\u3092\u5909\u9769\u3059\u308b\u3068\u3044\u3046\u4f7f\u547d\u306e\u5b9f\u73fe\u3092\u652f\u63f4\u3057\u3066\u3044\u307e\u3059\u3002Catalent\u306f\u3001\u958b\u767a\u304a\u3088\u3073\u88fd\u9020\u306e\u3042\u3089\u3086\u308b\u6bb5\u968e\u306b\u304a\u3044\u3066\u3001\u304a\u5ba2\u69d8\u306e\u30cb\u30fc\u30ba\u3092\u6e80\u305f\u3059\u30a8\u30f3\u30c9\u30c4\u30fc\u30a8\u30f3\u30c9\u306e\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3092\u30ab\u30b9\u30bf\u30de\u30a4\u30ba\u3057\u3066\u63d0\u4f9b\u3057\u307e\u3059\u3002\u4e16\u754c\u7d0440\u304b\u6240\u306e\u62e0\u70b9\u306b\u6570\u5343\u4eba\u306e\u79d1\u5b66\u8005\u3068\u6280\u8853\u8005\u3001\u305d\u3057\u3066\u6700\u65b0\u306e\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3092\u64c1\u3059\u308bCatalent\u306f\u3001\u6bce\u5e74\u6570\u5341\u5104\u56de\u5206\u306e\u3001\u751f\u6d3b\u306e\u8cea\u3092\u9ad8\u3081\u3001\u547d\u3092\u6551\u3046\u6cbb\u7642\u85ac\u3092\u60a3\u8005\u306b\u4f9b\u7d66\u3057\u3066\u3044\u307e\u3059\u3002\u8a73\u7d30\u306b\u3064\u3044\u3066\u306f\u3001\u3053\u3061\u3089\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002\u00a0www.catalent.com<\/a>.<\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066<\/b><\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/a>\u00a0\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308a\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u75be\u60a3\u306e\u7a2e\u985e\u3092\u554f\u308f\u305a\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\uff08NCT04945772<\/a>\uff09\u3001FDA\u3078\u306eBLA\u7533\u8acb\u304c\u9806\u6b21\u958b\u59cb\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u907a\u4f1d\u5b50\u691c\u67fb\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u30671\u56de\u6ce8\u5c04\u3059\u308b\u3060\u3051\u3067\u6295\u4e0e\u3067\u304d\u308b\u305f\u3081\u3001RP\u60a3\u8005\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\uff08NCT05417126<\/a>\uff09\u3092\u958b\u59cb\u3057\u3001\u00a0\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>\u00a02026\u5e74\u306b\u958b\u59cb\u4e88\u5b9a\u3067\u3059\u3002MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u30b9\u30bf\u30d5\u30a3\u30f3\u30fb\u30c7\u30a3\u30d5\u30a3\u30b7\u30eb\u75c7\uff08SD\uff09\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001SD\u306b\u3064\u3044\u3066\u306fRMAT\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u907a\u4f1d\u6027\u7db2\u819c\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\uff08IRD\uff09\u306b\u3064\u3044\u3066\u306fPMDA\u306e\u5148\u99c6\u3051\u6307\u5b9a\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3001IRD\u306b\u3064\u3044\u3066\u306fEMA\u304a\u3088\u3073SFDA\u306e\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u5730\u7406\u7684\u840e\u7e2e\uff08GA\uff09\u306b\u5bfe\u3059\u308bMCO\u306e\u7b2c2\u76f8\u30d7\u30ed\u30b0\u30e9\u30e0\u306f2026\u5e74\u306b\u958b\u59cb\u4e88\u5b9a\u3067\u3059\u3002IND\u7533\u8acb\u6e96\u5099\u4e2d\u306e\u305d\u306e\u4ed6\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u304c\u3042\u308a\u307e\u3059\u3002.<\/p>

\u63a5\u89e6\uff1a<\/b><\/p>

\u30ab\u30bf\u30ec\u30f3\u30c8
media@catalent.com<\/a><\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e
+1 (817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0July 7, 2026\u00a0—\u00a0Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and\u00a0Nanoscope Therapeutics, a biotechnology company committed to commercializing novel, disease-agnostic, vision-restoring therapies for patients with photoreceptor loss due to retinal degenerations, today announced an expanded partnership to support late-phase clinical and commercial supply of Nanoscope’s lead optogenetic gene therapy, MCO-010. Under the expanded partnership, Catalent will provide commercial-compliant packaging and distribution for MCO-010 and has secured the commercial packaging validation program to support Nanoscope’s Biologics License Application (BLA). A rolling submission with the U.S. Food and Drug Administration (FDA) is currently underway. “Catalent is pleased to expand our collaboration with Nanoscope as MCO-010 […]<\/p>\n","protected":false},"author":1,"featured_media":10204,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10203","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nCatalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T13:37:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T15:59:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010\",\"datePublished\":\"2026-07-07T13:37:54+00:00\",\"dateModified\":\"2026-07-07T15:59:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\"},\"wordCount\":608,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\",\"name\":\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"datePublished\":\"2026-07-07T13:37:54+00:00\",\"dateModified\":\"2026-07-07T15:59:27+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Catalent_V4FIN.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/07\\\/07\\\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","og_locale":"ja_JP","og_type":"article","og_title":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-07-07T13:37:54+00:00","article_modified_time":"2026-07-07T15:59:27+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Wilson PJ","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010","datePublished":"2026-07-07T13:37:54+00:00","dateModified":"2026-07-07T15:59:27+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/"},"wordCount":608,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","url":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/","name":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","datePublished":"2026-07-07T13:37:54+00:00","dateModified":"2026-07-07T15:59:27+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Catalent_V4FIN.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/07\/07\/catalent-and-nanoscope-therapeutics-expand-partnership-to-support-late-phase-development-and-commercial-supply-of-lead-optogenetic-gene-therapy-mco-010\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u30a6\u30a3\u30eb\u30bd\u30f3 PJ"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=10203"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10203\/revisions"}],"predecessor-version":[{"id":10211,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10203\/revisions\/10211"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/10204"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=10203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=10203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=10203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}